Background: Between the publication of the Union of International Cancer Control staging system (UICC) 7th and 8th editions, other staging algorithms for oropharyngeal squamous cell carcinoma (OPSCC) were proposed from Radiation Therapy Oncology Group (RTOG), MD Anderson Cancer Center (MDACC), and Yale University. Methods: With C-statistics, the above-mentioned five staging algorithms were compared for overall and relapse-free survival endpoints in a multi-institutional cohort of OPSCC cases (n = 338) treated with primary surgery. Results: Pathological UICC 8th ed yielded the highest C-indexes in the entire cohort and in the HPV− subset, whereas MDACC was superior for HPV+ OPSCC. RTOG was the simplest and holistic algorithm with a noninferior discriminatory power. Conclusion: UICC 8th ed, MDACC, and RTOG offer moderate and comparable efficacy for staging in this OPSCC patient cohort undergoing surgical treatment. Notable discrepancy between clinical and pathological UICC 8th ed algorithms poses potential concerns in diagnosis, treatment, research, and data management.
| INTRODUCTION
Human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma (OPSCC) is known to have a better prognosis compared to its smoking and alcohol associated counterpart. 1, 2 This prominent difference was shown in multiple series treated either with primary surgery 3, 4 or primary (chemo)radiotherapy ((C)RT). 5, 6 In 2010, Ang et al proposed a new staging system based on a recursive partitioning analysis done on a prospective randomized Radiation Therapy Oncology Group (RTOG) 0129 trial population with specific eligibility criteria. 5 This was the first classification which was taking the HPV status into consideration. Since then, various staging systems including HPV status were proposed with the main aim of improving the risk stratification for a better estimation of prognosis compared to Union of International Cancer Control staging system (UICC) 7th ed. 7 The UICC 8th ed was implemented in January 2017. 8 The new OPSCC staging is separated based on HPV status. For the HPV associated patients, the International Collaboration on Oropharyngeal Cancer Network Staging (ICON-S) was chosen for the clinical staging (cUICC). This staging algorithm was first developed in Canada 9 and validated in multiple centers from North America and northern Europe. 6 In these training and validation cohorts, only 2% of the patients were treated surgically. On the other hand, the development of the pathological staging was based on a retrospective multicenter study on patients mainly treated in North America and United Kingdom. 10 Of note, this pathological staging was not systematically validated such as the clinical staging algorithm at the time of implementation into the UICC 8th ed. Furthermore, the classification of nodal staging for all head and neck cancer subsites except for HPV associated OPSCC was based on a large dataset of oral cavity tumors. 8 In conclusion, it remains unclear, whether the UICC 8th ed can be applied in different areas of the world. Including this staging system, most recently proposed staging algorithms are heavily based on North American patient data mostly treated with primary (C)RT. 5, 6, [10] [11] [12] [13] However, smoking, alcohol consumption and sexual habits and prevalence rates of HPV associated and non-HPV associated OPSCC are strongly dependent on geography. Even among developed countries, these rates vary substantially. [14] [15] [16] [17] [18] Therefore, the prognostic stratification power of a staging system developed in a population may vary elsewhere. 19 Despite the remaining importance and high prevalence rates of non-HPV associated OPSCC, the contrast between the abundance of literature about HPV associated OPSCC and the scarcity of published works about non-HPV associated OPSCC in the last decade is striking. Among many proposed staging algorithms for OPSCC, only the RTOG and Dutch systems covered both non-HPV and HPV associated OPSCC, 5, 13, 20 whereas no new algorithm was proposed specifically for non-HPV associated OPSCC. Also in terms of differences in treatment modality, it is possible that a prognostic risk classification derived from a (C)RT cohort may perform worse than expected in a surgical cohort. 10 With this background, our aims were to (1) compare the prognostic qualities of five contemporary staging systems which were published until the official release of UICC 8th ed; (2) test their applicability in terms of risk prognostication; and (3) investigate the rates of inter-and intra-stage migration 21 among and within the c/pUICC 7th and 8th editions, respectively in our multi-institutional cohort treated by primary surgery.
| MATERIALS AND METHODS
A cohort of 338 patients diagnosed with OPSCC in seven participating centers were included in the analysis. The ethics committee of St. Gallen centrally approved the study protocol for all participating centers (reference number: 12/106/L), and the study was performed in accordance with the Declaration of Helsinki. Due to its retrospective design, it was not feasible and, therefore, not requested by the ethics committee to obtain written informed consent of each study participant. All patients were treated with primary surgery with or without adjuvant treatment based on the presence of pathological risk factors. Details of patient characteristics, diagnostic, and treatment procedures were published in a previous paper. 4 To optimize the diagnostic accuracy for HPV status, both p16 and HPV DNA positivity was sought as reported in the literature. 13, 22 A tumor was defined as HPV+ only if immunohistochemical p16 overexpression and HPV high risk type DNA by PCR were detected. Proposed systems other than UICC were chosen, if they met the following criteria: published before 2018, clearly proposed as a staging algorithm by the authors, not being a preliminary version of a later modified algorithm from the same working group, relied on variables which were available in our cohort. Concerning the latter criteria, some models included variables like comorbidity, nonstandard definition for smoking, hemoglobin level, values of epidermal growth factor receptor overexpression, maximum 18 F-fluorodeoxyglucose standard uptake which were absent in our database. 13, 20, [23] [24] [25] [26] The remaining eligible systems were tested: c/pUICC 7th and 8th editions, RTOG classification, 5 MD Anderson Cancer Centre (MDACC), 11 and Yale University 12 staging systems.
All staging algorithms were compared with Harrell's Concordance-index (C) 27 for the coprimary endpoints of overall survival (OS) and recurrence-free survival (RFS). Cstatistics were computed using the Inference of C function (Inf. Cval) of the survC1 package for the R language. The number of iterations of perturbation-resampling was set to the default of 1000. Additionally, hazard ratios (HR) for OS and RFS were computed using a cox proportional hazards regression model implemented in the coxph function of the survival package in the R language. The adjusted model compensates for smoking above 10 pack years (py), age, and extracapsular extension (ECE). The influences of those confounding variables for both endpoints were also reported separately. Due to missing data, alcohol consumption habits were not analyzed as a confounding variable. The Student's t test was used for mean comparison, the Wilcoxon ranksum test for median comparison and the chi-squared test for categorical variables. Finally, the stage migration effect between the UICC 7th and 8th ed and the agreement among clinical and pathological ECE (cECE and pECE, respectively) were compared both descriptively and by means of Cohen's weighted kappa. All tests were two-tailed and P values <0.05 were judged as statistically significant. The anonymized version of the data is available upon reasonable request to the corresponding author.
| RESULTS
Patient and disease characteristics as well as the corresponding differences between HPV+ and HPV− subgroups are provided in Table 1 . Between patients with HPV+ and HPV− OPSCC, statistically significant discrepancies were observed in smoking and alcohol consumption habits, cECE and adjuvant treatment indication. After the postoperative pathological examination for pECE, the previously statistically significant difference in ECE between HPV+ and HPV− patients disappeared. Contrary to expected, there was no significant age difference among patients diagnosed with HPV+ and HPV− OPSCC. Regardless of HPV status, concordance between cUICC and pUICC was higher within the 7th edition compared to the 8th ed (Table 2 ). In the 8th ed, this resulted in an upstaging rate of 19.4% in HPV−, and a down-staging rate of 45.4% in HPV+ patients.
Concerning the interstaging discordance, cUICC from the 7th to the 8th edition yielded a modest up-staging rate of 8.6% in HPV−, and a high down-staging rate of 93.9% in HPV+ patients. Similarly, pathological stage migration from 7th to the 8th ed manifested as up-staging in 21.1% of HPV−, and as down-staging in 92% in HPV+ patients (Table 3) .
Cohen's weighted kappa coefficients for the interagreement of the above-mentioned parameters are found in the Supporting Information Table S1 .
| Overall survival
When the entire cohort was evaluated, the C-indexes revealed a higher prognostic accuracy for RTOG, cUICC, and pUICC 8th ed in an increasing order, compared to UICC 7th ed ( Table 4 ). Almost no difference was observed in the HPV− patients between 7th and 8th ed of both cUICC and pUICC. In HPV+ patients, pUICC 8th ed was superior to pUICC 7th ed, whereas no improvement in prognostic accuracy was observed in cUICC versions. Despite an improvement within the pUICC (from 7th to 8th ed), both pUICC editions fell short of both cUICC editions for HPV+ OPSCC. MDACC slightly outperformed the remaining staging algorithms for HPV+ OPSCC. The RTOG classification markedly lost its prognostic power when it was applied separately on HPV+ and HPV− groups (Table 4) . Adjusted and unadjusted ordinal HRs with 95% confidence intervals (CI) for death are provided in Table 5 . Corresponding categorical HRs can be found in the Supporting Information Table S2 . For the entire cohort, RTOG, cUICC 8th ed, and pUICC 8th ed yielded statistically significant HRs for OS, with the highest observed in RTOG. For the HPV+ and HPV− OPSCC, no staging system showed any statistically significant risk stratification.
| Recurrence-free survival
In the entire cohort, RTOG, cUICC, and pUICC 8th ed outperformed the cUICC and pUICC 7th ed based on C-statistics (Table 4 ). There was no difference between the RTOG and cUICC 8th ed, whereas pUICC 8th ed showed a marginal benefit. For the HPV− patients, no meaningful difference was observed among any staging systems. In the HPV+ group, an increasing prognostic power in the following order was observed: cUICC 7th ed, pUICC 7th ed, Yale, cUICC 8th ed, pUICC 8th ed, and MDACC. As observed for the OS endpoint, RTOG lost its prognostic power for RFS when separately applied on HPV+ and HPV− groups (Table 4) . Adjusted and unadjusted ordinal HRs for recurrence or death are provided in Table 6 . Corresponding categorical HRs are outlined in the Supporting Information HPV− counterpart. 3, 4, [28] [29] [30] [31] [32] [33] Although no currently established single standard for the treatment of OPSCC exists, there are numerous ongoing trials about treatment deintensification in HPV+ OPSCC 34 and comparison of surgery and radiotherapy in terms of functional outcome (EORTC Bestof trial NCT02984410), for which an accurate staging plays a key role for risk stratification. As already mentioned, the increasing academic interest in HPV+ OPSCC and diminishing interest in HPV− OPSCC can only be partially justified with the change in epidemiology mainly in the developed world. The majority of OPSCC cases worldwide are still HPV− and mainly attributed to tobacco and alcohol exposure. To our knowledge, this is the first study comparing the recently proposed staging systems besides UICC in a cohort consisting of both HPV+ and HPV− OPSCC, all treated by surgery as the primary treatment modality. Recently, Mizumachi et al applied the cUICC 8th to a cohort (n = 195) of HPV+ and HPV− OPSCC patients treated with a heterogeneous treatment approach consisting of primary surgery or (C)RT. 19 They concluded that the 8th edition is more suitable for Japanese HPV− OPSCC patients. A similar study with a mixed cohort from Germany (n = 561) 17 came to the opposite conclusion, indicating a better prognostic stage discrimination of the 8th edition for HPV+ OPSCC, which is in line with our findings. Our results demonstrated a higher rate of ECE+ lymph node metastases of HPV+ OPSCC compared to HPV− cases. Moreover, the underestimation of cECE+ by imaging modalities was more prominent in HPV+ OPSCC. The specificity and sensitivity to accurately diagnose the presence of cECE+ with different imaging modalities vary between 70% and 90%. 35 Furthermore, a low intraobserver and interobserver agreement can pose problems for clinical diagnosis. 36 Due to major differences in the c/pN and c/pUICC of the 8th edition, we observed a high rate of postsurgical stage migration within the 8th edition compared to the 7th edition of UICC. This stage migration phenomenon is an expected result, and has been recently reported as down-staging in HPV+ OPSCC only cohorts. 19, 37 On the other hand, the more than double surgical up-staging rate within the 8th versus 7th edition (19.4% vs 8.6%) in our HPV− patients is mainly caused by the incorporation of ECE status into the nodal staging system of UICC 8th ed. The interstage migrations from the 7th to 8th editions in HPV+ and HPV− OPSCC to opposite directions in our series confirm the intention to widen the prognostic gap between two entirely different diseases. HPV+ cases underwent a dramatic down-staging both in clinical (93.9%) and pathological (92%) stages, whereas HPV− cases showed a rather modest up-staging pattern in clinical (8.6%) and pathological (21.1%) classifications. Except for one patient, all interstage migrations were unidirectional. The similarity between our interstage migration rates to a National Cancer Database study (n = 6465) 38 Except for the ICON-S (ie, cUICC 8th ed) which partially contained patients from northern Europe, all remaining staging algorithms were developed on cohorts diagnosed and treated in North America. Moreover, it is worth to note that the UICC 8th ed for HPV− OPSCC is based on a North American oral cavity data. 8 The comparison of five different staging algorithms in our cohort confirmed the applicability and moderate superiority of pUICC 8th ed for the OS estimation of HPV− OPSCC patients. For the estimation of RFS, RTOG and cUICC 8th ed demonstrated comparable prognostic accuracy, and pUICC 8th ed only showed a marginal benefit over them. When our cohort was separated by HPV status, only a slight improvement was revealed by the UICC 8th ed for HPV+ OPSCC, as the cUICC and pUICC 8th ed showed a moderately better accuracy to its previous edition and Yale, respectively. On the other hand, all of them were outperformed by MDACC. For the HPV− OPSCC, no substantial improvement was observed with the newer systems.
The prognostic power of the RTOG deserves a careful interpretation. As it is a three-tiered system which is largely separated by HPV and smoking status, two important problems arise when it is used in a purely HPV+ or HPV− cohort. First, it gets curbed down to a two-tiered system. Then an imbalanced patient distribution (and therefore a lack of events) occurs between the intermediate and low (if HPV+) or high (HPV−) risk groups. Therefore, RTOG seems to be only useful when used as a holistic staging system. In terms of RFS estimation, RTOG offers a more practical solution than the more complicated c/pUICC 8th ed, which is even not consistent within itself (discordance in clinical and pathological classifications). If, on the other hand, a higher prognostic accuracy is deemed as a more important factor than practicability, MDACC offers an even higher accuracy than UICC with a less complicated and onestop solution. However, it is worth to note that none of RTOG, MDACC, or pUICC 8th ed was validated until the UICC 8th ed was released. Moreover, investigators from John Hopkins Hospital recently compared the cUICC 8th ed and MDACC in a cohort of HPV+ OPSCC where 38% of the patients were treated with primary surgery. Contrary to our findings, they showed a superior risk stratification of the cUICC 8th ed over MDACC both for OS and RFS. 39 This difference to our findings may be caused by geographical factors, difference in primary treatment modalities, as well as due to the fact that the cUICC 8th ed and MDACC were developed on cohorts treated with (C)RT. We also evaluated the prognostic impact of age, smoking status, and ECE as well-established risk factors in the literature. Age was not a statistically significant prognostic factor. In the entire cohort, smoking above 10 py revealed a statistically significant impact on OS and RFS. This effect remained statistically significant for OS in the HPV+ patients. The loss of its significance for the HPV− OPSCC can be explained by 92% of our HPV− OPSCC cases being heavy smokers. In the literature, there are contradicting reports about the prognostic impact of tobacco exposure on HPV+ OPSCC. 5, 17 In our series, a negative prognostic impact of pECE+ on OS was only observed in HPV− OPSCC cases. This finding is in agreement with some of the previously published literature 35, 40 showing the lack of prognostic value of ECE status in HPV+ OPSCC, whereas contradicting evidence also exists. 37, 38, 41 Interestingly, cECE demonstrated a statistically significant impact on both endpoints of OS and RFS except for the HPV+ OPSCC patients' OS. This may be a result of either a type I error, or an unconventional hypothesisgenerating finding worth to be investigated further: The incidence of ECE+ is correlated with lymph node size. 42 Another fact is the prognostic impact of volumetric burden of the disease. 43, 44 Therefore, it is possible that the volumetric nodal burden of the disease actually plays a more important role than the "true" pECE, and ECE is a rather surrogate marker for nodal volume, and not necessarily vice versa.
It is important to emphasize that a C-index of 0.5 means that a prognostic model does not have a discriminatory power better than coincidence, and an index of 1 indicates an ideal model. In our current findings, the C-indexes vary between 0.45 and 0.64 which do not suggest a convincingly high prognostic accuracy. Nevertheless, it is interesting to witness the proclamation of marginal benefits for prognostic ability in the magnitude of 0.003 (C-index) as "improvements" in the literature. 45 As we see from cross-validation studies, even an externally validated system may not yield the same value in another cohort and can be outperformed by another staging algorithm. 12, 26 As the UICC staging committee members correctly pointed out, not only the prognostic accuracy, but also the practicality, physician compliance and worldwide applicability belong to the important aspects of an ideal staging system. 8 Although we value and respect the effort put forward by the UICC committee, in the light of the recently available data and based on our everyday experience, we fail to recognize those principles implemented in the UICC 8th ed. As reproduced in our study, both clinical and pathological staging algorithms of UICC 8th ed have a higher or at least noninferior prognostic value compared to other proposed and previously existing staging systems. As demonstrated in the literature and confirmed by our data, there is a ≥90% down-staging of HPV+ OPSCC with UICC 8th compared to 7th ed. Although we would like to deintensify the treatment of those patients, the phase III treatment deintensification trials for HPV+ OPSCC are ongoing, and the current treatment indications are still not based on HPV or any other risk-stratification introduced by the UICC 8th edition, which is based on the analyses of retrospective data of patients who were treated with conventional algorithms and guidelines. Currently, it is questionable, what kind of a practical consequence except for a more complex staging experience the UICC 8th ed, especially the pUICC will bring in everyday practice. The discrepancy between clinical and pathological staging algorithms is a known issue since the earlier versions of UICC. 46 However, with the UICC 8th ed, this gap due to intra-stage migration became vivid. In other words, even without gaining any new information through surgery (ie, same postoperative pathological tumor and nodal features as clinically identified via imaging, endoscopy, and manual examination), different clinical and pathological stages can be assigned to the very same patient. It is quite unconventional and counterintuitive to see a head and neck cancer patient not only differently staged but also differently processed for staging, only due to the chosen treatment modality. This poses potential concerns in diagnosis, 41 treatment, research, and data management. Our study has its limitations. Despite being quite homogenous, the cohort carries the intrinsic potential source of bias due to its retrospective nature. Furthermore, in the compared staging systems, different definitions for HPV status concerning p16 IHC and/or HPV DNA had been used, impairing the possibility to compare them.
In conclusion, with each of their strengths and weaknesses, the UICC 8th ed, MDACC, and RTOG systems offer moderate efficacy in similar magnitudes as staging algorithms for Swiss patients diagnosed with OPSCC undergoing surgical treatment. Building complex models only to achieve a marginal benefit is a futile effort. Beyond an acceptable risk stratification accuracy, pursuing practical utility should be the primary goal of developing future algorithms of the UICC, as the internationally accepted authority for cancer staging.
